Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions.

Clinical breast cancer - 1 Nov 2010

Bartlett John M S

Abstract excerpt

The phosphatidylinositol 3-kinase (PI3K)/Akt/ mammalian target of rapamycin (mTOR) pathway regulates a broad spectrum of physiologic and pathologic processes. In breast cancer mutation, amplification, deletion, methylation, and posttranslational modifications lead to significant dysregulation of this pathway leading to more aggressive and potentially drug-resistant disease. Multiple novel agents, targeting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Forecasting
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Patient Selection

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 21115427
DOI: 10.3816/CBC.2010.s.017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions.PMID 21115427Read ↗

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical ChallengesSemantic proximity Read ↗

New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer—Current State and Molecular Pathology PerspectiveSemantic proximity Read ↗

Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.Semantic proximity Read ↗

Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTORSemantic proximity Read ↗

Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.Semantic proximity Read ↗

Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort.Semantic proximity Read ↗

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted TherapeuticsSemantic proximity Read ↗

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.Semantic proximity Read ↗

Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.Semantic proximity Read ↗

The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive ReviewSemantic proximity Read ↗

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway.Semantic proximity Read ↗

Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyondSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.